Article

PDF
Access to the PDF text
Advertising


Free Article !

Archives of cardiovascular diseases
Volume 102, n° S1
page 10 (mars 2009)
Doi : 10.1016/S1875-2136(09)72144-8
Themes et posters

A011 Matrix metalloproteinase-12 gene regulation by PPAR alpha agonist in human monocyte-derived macrophages
 

I. Jguirim-Souissi 1, 2, L. Billiet 2, C. Cuaz-Perolin 2, M.-N. Slimane 1, M. Rouis 2
1 Research laboratory on atherosclerotic biological and genetic factors, Faculty of Medicine., Monastir, Tunisia 
2 UMR 7079 Physiologie et Physiopathologie, Université Pierre et Marie Curie-Paris 6, CNRS, Paris cedex 5, France 

@@#100979@@

MMP-12, a macrophage-specific matrix metalloproteinase with large substrate specificity, has been reported to be highly expressed in mice, rabbits and human atherosclerotic lesions. Increased MMP-12 from inflammatory macrophages is associated with several degenerative diseases such as atherosclerosis. Our results showed that IL-1b, a proinflammatory cytokine found in atherosclerotic plaques, increased both mRNA and protein levels of MMP-12 in human monocyte-derived macrophages (HMDM). Since peroxisome proliferator-activated receptors (PPAR) such as PPARa and PPARg are expressed in macrophages and because PPARs activation exert an anti-inflammatory effect on vascular cells; we have investigated the effect of PPARa and g isoforms on MMP-12 regulation in HMDM. Our results showed that MMP-12 expression (mRNA and protein) was down regulated in IL-1b-treated macrophages only in the presence of a specific PPARa agonist GW647 in a dose-dependent manner. In contrast, this inhibitory effect was abolished in IL-1b-stimulated peritoneal macrophages isolated from PPARa-/- mice and treated with the GW647 PPARa agonist. Moreover, reporter gene transfection experiments using different MMP-12 promoter constructs showed a reduction of the promoter activities by 50 % in IL-1b-stimulated PPARa pretreated cells. However, MMP-12 promoter analysis did not reveal the presence of a PPRE response element. The IL-1b effect is known to be mediated through the AP-1 binding site. Mutation of the AP-1 site, which is located at -81 in the MMP-12 promoter region relative to the transcription start site, followed by transfection analysis and gel shift experiments revealed that the inhibitory effect was the consequence of the protein-protein interaction between GW 647-activated PPARa and c-Fos or c-Jun transcription factors, leading to inhibition of their binding to the AP-1 motif. These studies suggest that PPARa agonists may be used as a therapeutically, not only for lipid disorders, but also to prevent inflammation and atheromatous plaque rupture, where their ability to inhibit MMP-12 expression in HMDM may be beneficial.

The full text of this article is available in PDF format.
The full text of this article is available in PDF format.
Click here to see it.

Top of the page

© 2009  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@